We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts
Read MoreHide Full Article
On Dec 23, we issued an updated research report on Bruker Corporation (BRKR - Free Report) . The company’s recent acquisition and collaborations are a strategic fit. However, currency fluctuations remain a drag. The stock carries a Zacks Rank #3 (Hold).
In the past three months, shares of Bruker have rallied 21.4% compared with its industry’s 10.2% rise. A year-over-year uptick in constant currency revenue growth witnessed across all geographies also looks impressive.
Additionally, we are upbeat about strong organic revenue growth, driven by strength in the Bruker Scientific Instruments (BSI) and BEST segments.
The Bruker Nano Surfaces group improved significantly during the quarter, fueled by uptrends in life science mass spectrometry solutions and microbiology.
The company is gaining strong synergy benefits from the acquisitions of Anasys, JPK and Alicona. In April 2019, NANO closed the acquisition of RAVE, a semiconductor mass repair business. This buyout contributed significantly to the company’s top line during the third quarter of 2019.
NANO's advanced x-ray business grew on consistent demand from academic and government customers. NANO surface tools revenues increased, courtesy of these integrations. The NANO group witnessed a high single-digit revenue rise in the last reported quarter on an organic basis, led by progress in all of NANO’s divisions.
However, a competitive landscape and macroeconomic woes pose challenges. Also, the contraction in the operating margin is concerning.
Key Picks
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , National Vision Holdings, Inc (EYE - Free Report) and ResMed Inc (RMD - Free Report) .
Haemonetics currently has a Zacks Rank #2 (Buy) and a projected long-term earnings growth rate of 13.5%.
ResMed’s long-term earnings growth rate is estimated at 14%. It currently flaunts a Zacks Rank #1.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts
On Dec 23, we issued an updated research report on Bruker Corporation (BRKR - Free Report) . The company’s recent acquisition and collaborations are a strategic fit. However, currency fluctuations remain a drag. The stock carries a Zacks Rank #3 (Hold).
In the past three months, shares of Bruker have rallied 21.4% compared with its industry’s 10.2% rise. A year-over-year uptick in constant currency revenue growth witnessed across all geographies also looks impressive.
Additionally, we are upbeat about strong organic revenue growth, driven by strength in the Bruker Scientific Instruments (BSI) and BEST segments.
The Bruker Nano Surfaces group improved significantly during the quarter, fueled by uptrends in life science mass spectrometry solutions and microbiology.
Bruker Corporation Price
Bruker Corporation price | Bruker Corporation Quote
The company is gaining strong synergy benefits from the acquisitions of Anasys, JPK and Alicona. In April 2019, NANO closed the acquisition of RAVE, a semiconductor mass repair business. This buyout contributed significantly to the company’s top line during the third quarter of 2019.
NANO's advanced x-ray business grew on consistent demand from academic and government customers. NANO surface tools revenues increased, courtesy of these integrations. The NANO group witnessed a high single-digit revenue rise in the last reported quarter on an organic basis, led by progress in all of NANO’s divisions.
However, a competitive landscape and macroeconomic woes pose challenges. Also, the contraction in the operating margin is concerning.
Key Picks
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , National Vision Holdings, Inc (EYE - Free Report) and ResMed Inc (RMD - Free Report) .
Haemonetics currently has a Zacks Rank #2 (Buy) and a projected long-term earnings growth rate of 13.5%.
National Vision’s long-term earnings growth rate is estimated at 17.8%. The company currently carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ResMed’s long-term earnings growth rate is estimated at 14%. It currently flaunts a Zacks Rank #1.
The Hottest Tech Mega-Trend of All
Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>